Compare IMNN & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMNN | ALUR |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 15.4M |
| IPO Year | 1985 | N/A |
| Metric | IMNN | ALUR |
|---|---|---|
| Price | $4.20 | $1.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $182.61 | $9.25 |
| AVG Volume (30 Days) | 33.4K | ★ 125.4K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.56 | $1.02 |
| 52 Week High | $41.22 | $16.81 |
| Indicator | IMNN | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 52.59 |
| Support Level | $3.83 | $1.61 |
| Resistance Level | $4.35 | $1.75 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 71.43 | 84.42 |
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.